pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jul 10·1 min read
save

US biotech firms grow more secretive amid rising competition from Chinese industry

Jul 10, 2026·read at Endpoints ↗Negative

US biotech companies are becoming more secretive as competition from China’s rapidly expanding biotech sector intensifies.

Janine Sengstack, a senior scientist at Junevity, says her team may have identified a breakthrough approach for diabetes and obesity by repressing specific genes after screening hundreds of candidates.

The article notes that increased secrecy could limit collaboration and affect how investors access information about U.S. drug development.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “US biotechs turn secretive as they fear competition from rising Chinese industry”

read at Endpoints ↗
84 words · retrieved Jul 10
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
RISING
drugs
Obesity2
topics
Obesity2Type 2 Diabetes2

related stories

  • Aug 26STAT+: Pharmalittle: We’re reading about a GSK shingles shot, U.S. employers dropping GLP-1 coverage, and moreSTAT
  • Aug 26Hansoh heralds China’s move from ‘follower’ to ‘frontrunner’ in biopharma raceFierce Biotech
  • Aug 14Opinion: U.S., U.K. health care systems share a fatal flawSTAT
  • Jul 23Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clearFierce Biotech
  • Jul 21Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesityBioSpace